Related Experiment Video
Updated: Jul 12, 2025
A Radio-telemetric System to Monitor Cardiovascular Function in Rats with Spinal Cord Transection and Embryonic Neural Stem Cell Grafts
Published on: October 7, 2014
Grb2 Expression in Acute Spinal Cord Injury After Methylprednisolone Intrathecal Injection in Rats
Yijun Zhou1, Guanwen Sun1, Changhong Li2
1The First People's Hospital of Changde, Changde Hospital Affiliated to Xiangya Medical College of Central South University, Hunan, People's Republic of China.
Objective:
This study aims to investigate the effect of methylprednisolone (MP) intrathecal injection on a rat model of acute spinal cord injury (ASCI).
Methods:
Allen's frame was used to establish a rat model of ASCI. MP and normal saline were intrathecally injected to Sprague-Dawley rats at 0, 3, 6, 8, 12, and 24 hours after ASCI, and injured spinal cord tissues were sterilely extracted after 24 hours of treatment. Isobaric tags for relative and absolute quantitation (iTRAQ) were coupled with 2-dimensional liquid chromatography tandem mass spectrometry to separate and identify differentially expressed proteins.
Results:
The expression of growth factor receptor-bound protein 2 (Grb2) was downregulated in the MP groups at 0 hours (iTRAQ ratio = 0.996), 3 hours (iTRAQ ratio = 0.737), 8 hours (iTRAQ ratio = 0.763), and 24 hours (iTRAQ ratio = 0.908) after injury compared with that in the control groups. No significant difference in Grb2 expression was observed between the control groups at 6 and 12 hours after ASCI.
Conclusions:
Standardized MP intrathecal injection after ASCI treatment reduces Grb2 activation in a rat ASCI model. Further studies should determine whether or not the same effect can be observed in human ASCIs.
Insights
Intrathecal methylprednisolone (MP) reduces growth factor receptor-bound protein 2 (Grb2) activation following acute spinal cord injury (ASCI) in rats. This suggests a potential therapeutic avenue for spinal cord injury treatment.
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Acute spinal cord injury (ASCI) is a devastating condition with limited treatment options.
- Methylprednisolone (MP) is a corticosteroid with anti-inflammatory properties that has been investigated for ASCl treatment.
- Understanding the molecular mechanisms underlying MP's effects is crucial for optimizing its therapeutic potential.
Purpose of the Study:
- To investigate the impact of intrathecal methylprednisolone (MP) administration on protein expression in a rat model of acute spinal cord injury (ASCI).
- To identify specific proteins affected by MP treatment at various time points post-ASCI.
Main Methods:
- An acute spinal cord injury (ASCI) rat model was established using Allen's frame.
- Intrathecal injections of methylprednisolone (MP) or normal saline were administered at 0, 3, 6, 8, 12, and 24 hours post-ASCI.
- Proteomic analysis using isobaric tags for relative and absolute quantitation (iTRAQ) coupled with 2D-LC-MS/MS was performed on injured spinal cord tissues.
Main Results:
- Methylprednisolone (MP) treatment led to the downregulation of growth factor receptor-bound protein 2 (Grb2) expression at 0, 3, 8, and 24 hours post-ASCI.
- No significant changes in Grb2 expression were observed at 6 and 12 hours post-ASCI in the MP-treated groups compared to controls.
- These findings indicate a time-dependent effect of MP on Grb2 regulation following spinal cord injury.
Conclusions:
- Intrathecal methylprednisolone (MP) administration effectively reduces growth factor receptor-bound protein 2 (Grb2) activation in a rat model of acute spinal cord injury (ASCI).
- The study highlights Grb2 as a potential molecular target for MP in spinal cord injury.
- Further research is warranted to explore the efficacy and mechanisms of MP in human ASCI cases.
